* Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected
to show a
fall in quarterly revenue when it reports results on August 12
(estimated) for the period ending June 30 2024
* The Bridgewater New Jersey-based company is expected to
report
a 18.5% decrease in revenue to $110 thousand from $135 thousand
a year ago, according to the estimate from one analyst, based on
LSEG data.
* LSEG's mean analyst estimate for Vyne Therapeutics Inc is
for a
loss of 19 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5.75, above its last closing price of $1.77.
This summary was machine generated August 9 at 18:07 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)